多中心临床试验中血管内治疗患者无效再通的发生率与预测因素
基于IMS III试验血管内治疗组的130例近完全或完全再通(TICI 2b/3)患者,47%出现无效再通(3个月mRS 3-6)。多因素分析显示基线NIHSS(OR 1.3)、女性(OR 3.0)和发病至血管内治疗开始时间(OR 1.2)为无效再通的独立预测因素,其中治疗延迟是唯一可干预的危险因素。
要点
- 再通后约47%患者仍无临床获益,报告时需结合3个月mRS而非仅看TICI分级。
- 基线NIHSS每升高1分,无效再通OR为1.3(95%CI 1.1-1.4),读片时需关注入院神经功能状态。
- 女性无效再通风险约为男性的3倍(OR 3.0,95%CI 1.1-8.2),属不可干预因素。
核心结论
- 在IMS III试验血管内治疗组中,无效再通常见(47%);治疗延迟是唯一可干预的危险因素,女性与高NIHSS为不可干预因素,需寻找针对后两者的额外策略。
研究设计与样本
- IMS III多中心临床试验血管内治疗组的回顾性分析,纳入近完全或完全再通(TICI 2b和3级)患者130例,按3个月mRS分为有意义的再通(mRS 0-2)与无效再通(mRS 3-6),行多因素分析寻找无效再通的预测因素。
诊断标准与关键数值
- 再通标准为血管造影TICI 2b或3级;无效再通定义为虽达血管造影再通但3个月mRS 3-6,有意义的再通为mRS 0-2。多因素分析中基线NIHSS的OR 1.3(95%CI 1.1-1.4)、女性OR 3.0(95%CI 1.1-8.2)、发病至血管内治疗开始时间OR 1.2(95%CI 1.1-1.3)为独立预测因素。
临床应用与阅片要点
- 报告再通结果时,除TICI分级外应结合3个月mRS评估临床获益;对女性、高基线NIHSS及发病至治疗开始时间较长者,可在报告中提示无效再通风险较高(原文作者结论)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The phenomenon of futile recanalization, defined as lack of clinical benefit despite angiographic recanalization, is an important limitation of endovascular treatment for acute ischemic stroke. We aim to characterize the occurrence and predictors of futile recanalization in the endovascular arm of the Interventional Management of Stroke (IMS) III trial.
METHODS: Patients with near complete or complete recanalization (TICI grades 2b and 3) were divided according to functional outcome at 3 months into "meaningful recanalization," defined as mRS score 0-2, and "futile recanalization," mRS score 3-6. Multivariate analysis was performed to identify predictors of futile recanalization.
RESULTS: Futile recanalization was observed in 61 (47%) of 130. Compared to meaningful recanalization group, the futile recanalization group had higher proportion of women (62.3 vs. 43.5%; p = 0.032), higher incidence of diabetes mellitus (29.5 vs. 8.7%; p = 0.004) and coronary artery disease (27.9 vs. 13%; p = 0.05), higher baseline National Institutes of Health Stroke Scale (NIHSS) scores (median [range] 19 [11-31] vs. 15 [8-26], p < 0.001), higher baseline serum glucose (7.6 ± 2.6 vs. 6.7 ± 1.7 mmol/L; p = 0.039), and longer onset-to-start of endovascular treatment time (265.8 ± 48.3 vs. 239.2 ± 47.7 min; p = 0.007). In multivariate analysis, NIHSS (OR 1.3; 95% CI 1.1-1.4), female gender (OR 3.0; 95% CI 1.1-8.2), and onset-to-start of endovascular treatment time (OR 1.2; 95% CI 1.1-1.3) were independent predictors of futile recanalization.
CONCLUSION: In IMS III, futile recanalization was common. Delay in endovascular treatment is the only modifiable risk factor. Additional strategies for non-modifiable risk factors-female gender and high NIHSS-need to be identified.
引用
- Hussein HM, Saleem MA, Qureshi AI, et al. Rates and predictors of futile recanalization in patients undergoing endovascular treatment in a multicenter clinical trial. Neuroradiology. 2018. PMID: 29574600. doi:10.1007/s00234-018-2016-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。